Genen­tech teams with lit­tle Novome on IBD re­search, look­ing to col­o­nized bac­te­ria af­ter a se­vere set­back

Back at the be­gin­ning of 2020, Genen­tech vet Blake Wise jumped to a start­up in the Bay Area called Novome, join­ing at the same time a syn­di­cate came to­geth­er to of­fer a $33 mil­lion launch round for a plat­form biotech out to col­o­nize the gut with en­gi­neered strains of bac­te­ria that work as ther­a­peu­tics.

To­day, Wise is join­ing up with re­searchers at his al­ma mater to team on a new pro­gram that will look to break new ground in IBD — a new field for the biotech and a top in­ter­est at Genen­tech, where Roche’s James Sabry has now ex­e­cut­ed his lat­est deal.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER